Endurant Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Endurant Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,400	Closed	-$1.83M	–	82
2022 Q1	$1.83M	Buy	15,400 +9,331	+154%	+$1.16M	0.48%	40
2021 Q4	$836K	Buy	+6,069	New	+$772K	0.2%	62
2019 Q2	–	Sell	-7,479	Closed	-$385K	–	90
2019 Q1	$385K	Buy	+7,479	New	+$323K	0.15%	65
2018 Q1	–	Sell	-10,300	Closed	-$278K	–	92
2017 Q4	$278K	Buy	+10,300	New	+$284K	0.09%	74

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Endurant Capital Management's BHVN Position: Q2 2022 in Review

Endurant Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 15,400 shares — an estimated $1.83M sold.

Endurant Capital Management first reported a position in BHVN in Q4 2017 and held it in 4 quarters. The position peaked at $1.83M in Q1 2022. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Endurant Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Endurant Capital Management sold 15,400 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $1.83M.
Endurant Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 4 quarters.
Endurant Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.83M in Q1 2022.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.